Biobeat Secures $50M to Uncuff the Future of Blood Pressure Monitoring

By Matthew Richardson

PETAH TIKVA, Israel & BOCA RATON, Fla. – December 30, 2025 – Biobeat Technologies, Ltd., an innovator in medical-grade wearables, has closed a $50 million Series B financing round to accelerate the U.S. commercialization of its revolutionary patch-worn, cuff-less ambulatory blood pressure monitor (ABPM). The funding signals a major vote of confidence from top-tier healthcare investors and could mark a pivotal moment in the management of hypertension, a condition affecting nearly half of all American adults.

The financing was led by prominent global healthcare investors Ally Bridge Group, OrbiMed Advisors, and Elevage Medical, with a strategic investor also participating. The capital injection is earmarked for an aggressive expansion in the United States, where over 100 million people live with hypertension, often called the “silent killer” for its lack of obvious symptoms.

The Problem with the Cuff

For decades, the gold standard for out-of-clinic blood pressure assessment has been Ambulatory Blood Pressure Monitoring (ABPM). This method involves a patient wearing a portable device with an inflatable cuff on their arm for 24 hours, which automatically takes readings at regular intervals. ABPM provides a comprehensive picture of a patient's blood pressure fluctuations, including the critical nighttime period, offering far more diagnostic insight than a single reading in a doctor's office.

Despite its clinical value, traditional ABPM has been chronically underutilized. The primary culprits are low patient compliance and logistical hurdles. Patients often find the repeated, noisy inflation cycles of the cuff to be disruptive to daily activities and, most significantly, sleep. This discomfort leads many to abandon the test early, resulting in incomplete or skewed data. For clinical staff, managing the devices, retrieving the data, and ensuring proper sanitation between uses presents a significant operational burden.

This gap in care means that millions of hypertensive patients are diagnosed and managed based on less-than-optimal data, potentially leading to misdiagnosis, ineffective treatment titration, and poor long-term health outcomes.

A Patch for a Pressing Problem

Biobeat aims to solve this long-standing challenge with its novel monitoring system. The company has developed the first FDA-cleared, 24-hour ABPM solution that is entirely cuff-less. The system uses a small, disposable sensor patch worn on the upper torso. This discreet patch allows patients to go about their lives—working, exercising, and sleeping—completely undisturbed.

At the heart of the technology are photoplethysmography (PPG) sensors, which use light to measure changes in blood volume in the microvasculature. Advanced algorithms then process these signals to continuously and accurately derive not just blood pressure but also other vital signs like pulse rate, respiratory rate, and blood oxygen saturation. The company received its initial FDA 510(k) clearance in 2019, a landmark moment for cuff-less monitoring technology.

Clinical validation has been a cornerstone of Biobeat's strategy. Peer-reviewed studies have demonstrated that the device's accuracy meets stringent international standards, with measurements showing a mean difference of less than 5.0 mmHg compared to traditional cuff-based methods. At the conclusion of the 24-hour monitoring period, the patient simply disposes of the patch. A comprehensive report is automatically generated and can be integrated directly into a hospital's electronic medical records, streamlining the workflow for clinicians.

"We believe that Biobeat will have a profoundly positive impact on clinical utilization of ABPM, similar to what was experienced with ambulatory ECG monitoring once a patch-worn device became available," said Raymond W. Cohen, Executive Chairman of Biobeat, in a statement.

Smart Money Bets on a Cuff-less Future

The $50 million investment is more than just capital; it's a strategic endorsement from some of the most respected names in healthcare venture capital. The new investors—Ally Bridge Group, OrbiMed, and Elevage Medical—are known for backing disruptive technologies with the potential to become new standards of care. As part of the deal, Steven Plachtyna of Ally Bridge, Dina Chaya of OrbiMed, and Evan Melrose of Elevage have joined Biobeat's Board of Directors, bringing deep industry and operational expertise.

Ally Bridge Group focuses on high-impact life science innovations, while OrbiMed has a long track record of building market-leading healthcare companies. Elevage Medical, a platform established by Patient Square Capital, is specifically dedicated to accelerating growth-stage medtech companies. Their collective investment suggests a strong belief in both Biobeat's technology and its ability to capture a significant share of the ABPM market, which is projected to grow substantially in the coming years, driven by the rising prevalence of cardiovascular disease.

Arik Ben Ishay, CEO of Biobeat, expressed his enthusiasm for the next phase. "This is an exciting time for the company as we bring on a talented field sales team to expand commercialization of our novel ABPM system," he stated. "Based on our winning, clinically validated embodiment, the time has finally arrived to make ABPM a true standard of care."

Navigating the Path to a New Standard

While Biobeat's solution is promising, the journey to widespread clinical adoption involves navigating a competitive and cautious landscape. The cuff-less blood pressure monitoring space is heating up, with tech giants and medical device startups alike racing to develop wearable solutions. However, a primary hurdle for the entire category is proving clinical-grade accuracy.

Leading medical bodies, including the American Heart Association, have expressed caution, noting that while cuff-less devices hold great promise, many have not yet demonstrated the precision required to be used for diagnosing or managing treatment for high blood pressure. This makes Biobeat's existing FDA clearance and body of published clinical evidence crucial differentiators.

By focusing on the validated, 24-hour ABPM use case rather than casual consumer monitoring, Biobeat is positioning itself as a clinical tool designed to solve a specific medical problem. The company's strategy mirrors the successful trajectory of patch-based cardiac monitors, which transformed ambulatory ECGs from a cumbersome procedure to a routine diagnostic test. With its new funding and powerful backers, Biobeat is now poised to prove that its comfortable, continuous monitoring patch can finally make comprehensive blood pressure assessment an accessible and widely used tool in the fight against hypertension.